Literature DB >> 27341700

Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.

Shigeaki Sunada1,2, Hideki Kanai1,2, Younghyun Lee2, Takeshi Yasuda3, Hirokazu Hirakawa2, Cuihua Liu2, Akira Fujimori2, Mitsuru Uesaka1, Ryuichi Okayasu4.   

Abstract

High-linear energy transfer (LET) heavy ions have been increasingly employed as a useful alternative to conventional photon radiotherapy. As recent studies suggested that high LET radiation mainly affects the nonhomologous end-joining (NHEJ) pathway of DNA double strand break (DSB) repair, we further investigated this concept by evaluating the combined effect of an NHEJ inhibitor (NU7441) at a non-toxic concentration and carbon ions. NU7441-treated non-small cell lung cancer (NSCLC) A549 and H1299 cells were irradiated with X-rays and carbon ions (290 MeV/n, 50 keV/μm). Cell survival was measured by clonogenic assay. DNA DSB repair, cell cycle distribution, DNA fragmentation and cellular senescence induction were studied using a flow cytometer. Senescence-associated protein p21 was detected by western blotting. In the present study, 0.3 μM of NU7441, nontoxic to both normal and tumor cells, caused a significant radio-sensitization in tumor cells exposed to X-rays and carbon ions. This concentration did not seem to cause inhibition of DNA DSB repair but induced a significant G2/M arrest, which was particularly emphasized in p53-null H1299 cells treated with NU7441 and carbon ions. In addition, the combined treatment induced more DNA fragmentation and a higher degree of senescence in H1299 cells than in A549 cells, indicating that DNA-PK inhibitor contributes to various modes of cell death in a p53-dependent manner. In summary, NSCLC cells irradiated with carbon ions were radio-sensitized by a low concentration of DNA-PK inhibitor NU7441 through a strong G2/M cell cycle arrest. Our findings may contribute to further effective radiotherapy using heavy ions.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  DNAPK protein; G2 cell cycle arrest; heavy ions; non-small cell lung cancer; p53 genes

Mesh:

Substances:

Year:  2016        PMID: 27341700      PMCID: PMC5021029          DOI: 10.1111/cas.12998

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


Heavy‐ion radiation therapy has been increasingly utilized due to its lesser side effects compared to conventional photon radiation therapy;1, 2 tumor tissue can be well targeted by physically adjusting the Bragg peak on the tumor area, and a high‐linear energy transfer (LET) beam can induce more effective tumor cell killing than low‐LET beams.3, 4, 5 Another strategy to improve the outcome of radiotherapy would be to use a radio‐sensitizer, which enhances radiation‐induced cell killing by targeting DNA damage response.6, 7, 8, 9 Although many studies are available on low‐LET radiation combined with sensitizers, further biological studies are necessary in the combined regimen of radio‐sensitizer and heavy ions for future clinical applications. There are two main pathways for DNA double‐strand break (DSB) repair: homologous recombination (HR) and nonhomologous end joining (NHEJ). NHEJ is a dominant pathway in DSB repair induced by low‐LET radiation, such as X‐rays and γ‐rays,10 while NHEJ has been shown to be suppressed to some extent and the HR pathway utilized more in DSB induced by high‐LET radiation.11, 12, 13 Furthermore, Takahashi et al.14 reported that when using HR and NHEJ pathway‐deficient mouse embryonic fibroblasts, high‐LET radiation caused significant radio‐sensitization even in NHEJ‐defective cells. Their study suggests that the NHEJ pathway is still dominant in DSB repair induced by high‐LET radiation. Therefore, it is important to study how cells with reduced or inhibited NHEJ respond to high‐LET heavy‐ion radiation. DNA‐PKcs is one of the key proteins in the NHEJ pathway, and many studies report radio‐sensitization as a consequence of DNA‐PK inhibition.15, 16, 17, 18 In particular, NU7441 has often been studied as an effective specific DNA‐PK inhibitor; this specificity was confirmed by the use of DNA‐PKcs defective cells, which did not show any radio‐sensitization with NU7441 treatment.9 In this study, we investigate the combined effect of NU7441 and carbon ion radiation in human non‐small cell lung cancer (NSCLC) cells. We find that the nontoxic concentration of NU7441 causes significant radio‐sensitization with X‐rays and carbon ions in NSCLC cells, with little effect on DSB repair; strong G2/M arrest is found to be associated with this sensitization.

Materials and Methods

Cell culture

Non‐small cell lung cancer cell lines A549 and H1299 cells were obtained from Riken BRC (Tsukuba, Japan) and the American Type Culture Collection (Manassas, VA, USA), respectively. A549 and H1299 were grown in MEMα and RPMI‐1640, respectively, and supplemented with 10% (v/v) FBS. Normal human fibroblast cell line HFL1 cells were obtained from Riken BRC and were grown in MEMα supplemented with 15% FBS. All cells were maintained in a 37°C incubator with 5% CO2. Exponentially growing cells were used in the present study.

Irradiation and drug treatment

Cells were irradiated with 290 MeV/n carbon ions (LET: 50 keV/μm) at the Heavy Ion Medical Accelerator in Chiba (HIMAC). The dose rate for carbon ions was 1 Gy/min. X‐ray irradiation was performed using a TITAN‐320 (200 kV, 20 mA, Shimadzu, Kyoto, Japan) at a dose rate of 1 Gy/min. NU7441, a specific DNA‐PK inhibitor, was purchased from Cayman Chemical (Ann Arbor, MI, USA). NU7441 was dissolved in DMSO and stored at −20°C in a freezer. Cells were pretreated with NU7441 1 h before irradiation, and the drug was kept throughout the experiment.

Clonogenic survival assay

Cells were seeded at concentrations that may yield approximately 50–100 colonies per dish after 10–12 days. The colonies were fixed with 100% ethanol and stained with 0.1% crystal violet solution. The colonies containing more than 50 cells were scored.

Flow cytometry

γ‐H2AX (a DSB marker), cell cycle distribution and senescence‐associated beta‐galactosidase (SA‐βGal) signals were analyzed using a FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA) flow cytometer. For detection of DSB, the γ‐H2AX signal was measured according to protocol described elsewhere.19 Cells were trypsinized, washed with cold PBS twice and stained with γ‐H2AX antibody FITC conjugate (0.6 μg/mL; Merck Millipore, Billerica, MA, USA) on ice overnight. The cells were then suspended and analyzed. For cell cycle analysis, cells were trypsinized, washed with cold PBS, fixed in 70% ethanol and stored at −20°C. Cells were stained with propidium iodide (PI) at 50 μg/mL in the presence of RNase (1 mg/mL) for 30 min on ice and then analyzed. For the SA‐βGal assay, the SA‐βGal signal was measured according to a protocol described elsewhere.20 Cells were labeled with C12FDG (20 μg/mL; Setareh Biotech, Eugene, OR, USA) as fluorescent substrates of beta‐galactosidase for 2 h in culture medium 3 days after irradiation, washed with PBS twice, trypsinized, resuspended in cold PBS and then analyzed. At least 10 000 cells were counted for analysis in all assays.

Western blotting

Anti‐p21 and anti‐GAPDH antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). For immunoblot analysis, proteins were separated by SDS‐PAGE, transferred onto Immobilon‐P membranes (Merck Millipore), and detected using the Western‐Light Plus Chemiluminescent Detection System (Tropix, Bedford, MA, USA) using appropriate secondary antibodies. Quantification was carried out using an LAS‐4000 mini luminoimaging analyzer (Fujifilm, Tokyo, Japan).

Statistical analysis

All data were analyzed using GraphPad Prism 6 (GraphPad, La Jolla, CA, USA). Statistical comparison of the mean values was performed using Student's t‐test and P < 0.05 was considered to be statistically significant.

Results

Non‐toxic concentration of NU7441 induces radio‐sensitization in non‐small cell lung cancer cells irradiated with low‐LET and high‐LET radiation

Cellular toxicity of NU7441 was evaluated in normal HFL1 cells and NSCLC cells using a clonogenic survival assay. HFL1 cells showed a concentration‐dependent decrease in plating efficiency, and this was more distinct for the concentrations higher than 1 μM (Fig. 1a). NSCLC cells showed a clear drop in plating efficiency at 3 μM (Fig. 1b). These results indicate that 0.3 μM of NU7441 is nontoxic in both normal and cancer cells. A clonogenic survival assay was performed with this nontoxic concentration of NU7441. Significant radio‐sensitization was confirmed in NU7441‐treated NSCLC cells, not only with X‐rays but also with carbon ions (Fig. 1c,d). The relative biological effectiveness (RBE) of carbon ions (50 keV/μm) compared to X‐rays and the sensitization enhancement ratio (SER) of NU7441 (0.3 μM) were calculated based on the D 10 values. Carbon ions showed an RBE of 2.15 in A549 cells and 1.87 in H1299 cells. NU7441 gave an SER of 1.77 (X‐rays) and 1.55 (carbon ions) in A549 cells and 1.94 (X‐ray) and 1.58 (carbon ions) in H1299 cells. Judging from these analyses, carbon ions caused more effective cell killing in A549 than H1299 cells, while NU7441 induced higher radio‐sensitization with X‐rays than carbon ions in H1299 cells, and the degree of sensitization was smaller for A549 cells.
Figure 1

Both X‐rays and carbon ions induce radio‐sensitization in non‐small cell lung cancer (NSCLC) cells with nontoxic conce ntrations of NU7441 treatment. The cellular toxicities of NU7441 in HFL1 cells (a) and NSCLC cells (b) were determined by clonogenic survival assay. The survival fraction in A549 (c) and H1299 (d) cells after indicated treatments were determined by clonogenic survival assay. Colonies containing more than 50 cells were scored. Data represent mean ± SD from three independent experiments.

Both X‐rays and carbon ions induce radio‐sensitization in non‐small cell lung cancer (NSCLC) cells with nontoxic conce ntrations of NU7441 treatment. The cellular toxicities of NU7441 in HFL1 cells (a) and NSCLC cells (b) were determined by clonogenic survival assay. The survival fraction in A549 (c) and H1299 (d) cells after indicated treatments were determined by clonogenic survival assay. Colonies containing more than 50 cells were scored. Data represent mean ± SD from three independent experiments.

Low concentration of NU7441 does not seem to show double strand break‐repair inhibition in irradiated cells

Double strand break repair after irradiation was evaluated by analyzing γ‐H2AX signals. Three micromolar of NU7441 showed significantly increased persistent γ‐H2AX signals compared to the control, even in carbon‐irradiated cells showing clear DSB‐repair inhibition. In contrast, 0.3 μM of NU7441 did not seem to show a significant shift from the control in γ‐H2AX signals, except for a very slight increase in the 24‐h sample in some cases (Fig. 2a–d). Our results suggest that the low concentration of NU7441 (0.3 μM) did not induce obvious DSB repair inhibition in spite of its marked radio‐sensitization effect at the cell survival level (Fig. 1c,d).
Figure 2

Low concentration of NU7441 does not seem to show double strand break (DSB) repair inhibition in X‐ray‐irradiated and carbon‐irradiated non‐small cell lung cancer (NSCLC) cells. The quantification of DSB was analyzed by γ‐H2AX signal using flow cytometry 1, 4 and 24 h after 4 Gy of irradiation. The fold change of the γ‐H2AX level at the indicated time after irradiation was calculated with respect to control (without irradiation and NU7441). DSB repair kinetics with 0.3 and 3 μM NU7441 were analyzed in A549 cells irradiated with X‐rays (a) and carbon ions (c), and in H1299 cells irradiated with X‐rays (b) and carbon ions (d). Data represent mean ± SD from at least two independent experiments.

Low concentration of NU7441 does not seem to show double strand break (DSB) repair inhibition in X‐ray‐irradiated and carbon‐irradiated non‐small cell lung cancer (NSCLC) cells. The quantification of DSB was analyzed by γ‐H2AX signal using flow cytometry 1, 4 and 24 h after 4 Gy of irradiation. The fold change of the γ‐H2AX level at the indicated time after irradiation was calculated with respect to control (without irradiation and NU7441). DSB repair kinetics with 0.3 and 3 μM NU7441 were analyzed in A549 cells irradiated with X‐rays (a) and carbon ions (c), and in H1299 cells irradiated with X‐rays (b) and carbon ions (d). Data represent mean ± SD from at least two independent experiments.

Low concentration of NU7441 causes significant G2/M arrest in irradiated H1299 cells

To study the mechanism of radio‐sensitization at the low concentration (0.3 μM) of NU7441, we investigated the cell cycle distribution in tumor cells 24 h after the combined treatment. As shown in Figure 3, both NU7441 and X‐rays alone did not seem to cause a significant change in cell cycle distribution compared to the control. However, G2/M arrest was clearly observed in the combined treatment of NU7441 and radiation. The most intense G2/M arrest was induced by the combination of NU7441 and carbon ions in both cell lines. Interestingly, with carbon irradiation alone, A549 cells showed more G2/M arrest than H1299 cells, but after NU7441 and carbon irradiation, G2/M arrest was more distinct in H1299 cells than A549 cells.
Figure 3

Non‐small cell lung cancer (NSCLC) cells treated with NU7441 (0.3 μM) and radiation show significant G2/M arrest. Cell cycle distribution after indicated treatments was analyzed 24 h after 4 Gy of irradiation using flow cytometry. The figures show the representative histogram and the stacked chart of cell cycle distribution in A549 cells (a, c) and in H1299 cells (b, d). Data represent mean ± SD from at least three independent experiments.

Non‐small cell lung cancer (NSCLC) cells treated with NU7441 (0.3 μM) and radiation show significant G2/M arrest. Cell cycle distribution after indicated treatments was analyzed 24 h after 4 Gy of irradiation using flow cytometry. The figures show the representative histogram and the stacked chart of cell cycle distribution in A549 cells (a, c) and in H1299 cells (b, d). Data represent mean ± SD from at least three independent experiments.

Irradiated H1299 cells were more effectively killed by NU7441

To investigate the mode of cell death, DNA fragmentation and cellular senescence were studied. For DNA fragmentation analysis, the sub‐G1 population in NSCLC cells was evaluated for 3 days. A very small portion of X‐irradiated A549 cells became sub‐G1 phase even with NU7441, while carbon irradiation increased the sub‐G1 population regardless of NU7441 presence 3 days after treatment (Fig. 4a). We were not able to confirm a difference between A549 and H1299 cells 1 day after irradiation; however, H1299 cells treated with NU7441 (0.3 μM) and exposed to X‐rays and carbon ions showed a remarkable increase in the sub‐G1 population after day 2 (Fig. 4b). For cellular senescence analysis, an SA‐βGal assay in NSCLC cells was performed 3 days after irradiation. SA‐βGal–positive cells increased significantly in carbon‐irradiated A549 cells and in H1299 cells treated with NU7441 and carbon irradiation (Fig. 5a,b). Because the p53p21 signal pathway is an important senescence pathway, and the p53 status in A549 and H1299 cells are wild type and null, respectively, p21 protein expression was measured in these cells. As shown in Figure 5(c), p21 expression in A549 cells was consistent with the result of the SA‐βGal assay; in contrast, no activation was observed in H1299 cells. These results indicate that cellular senescence was observed in p53‐null H1299 cells, suggesting that this process does not depend on p53 status.
Figure 4

NU7441 (0.3 μM) causes a remarkable increase of DNA fragmentation in irradiated H1299 cells. DNA fragmentation after indicated treatments was determined by analyzing the sub‐G1 population in A549 cells (a) and H1299 cells (b) 1, 2 and 3 days after 4 Gy of irradiation using flow cytometry. Data represent mean ± SD from at least three independent experiments.

Figure 5

NU7441 (0.3 μM) enhances cellular senescence in irradiated H1299 cells. Cellular senescence after indicated treatments was determined by analyzing SA‐βGal using flow cytometry in A549 cells (a) and H1299 cells (b) and p21 expression in both cells (c) using western blotting 3 days after 4 Gy of irradiation. Data represent mean ± SD from at least three independent experiments.

NU7441 (0.3 μM) causes a remarkable increase of DNA fragmentation in irradiated H1299 cells. DNA fragmentation after indicated treatments was determined by analyzing the sub‐G1 population in A549 cells (a) and H1299 cells (b) 1, 2 and 3 days after 4 Gy of irradiation using flow cytometry. Data represent mean ± SD from at least three independent experiments. NU7441 (0.3 μM) enhances cellular senescence in irradiated H1299 cells. Cellular senescence after indicated treatments was determined by analyzing SA‐βGal using flow cytometry in A549 cells (a) and H1299 cells (b) and p21 expression in both cells (c) using western blotting 3 days after 4 Gy of irradiation. Data represent mean ± SD from at least three independent experiments.

Discussion

In this report, we found that a nontoxic concentration of DNA‐PK inhibitor, NU7441, caused significant radio‐sensitization both in X‐irradiated and carbon‐irradiated NSCLC cells; for x‐rays, SER are 1.77 and 1.94, and for carbon ions SER are 1.55 and 1.58 depending on cell lines (Fig. 1). In previous reports,9, 21, 22, 23, 24 much higher concentrations of this drug were used to induce radio‐sensitization. The drug concentration of 0.3 μM used in this study, 1/3 to 1/30 the concentrations used in the abovementioned publications, did not affect cell viability. Therefore, 0.3 μM of NU7441 is a useful strategy for radio‐sensitization. Our strategy is particularly beneficial for particle radiation therapy including heavy ions as its irradiation beams mostly hit the tumor tissue with little sensitizing effect on surrounding normal tissues. The sensitization ratio is lower in cells irradiated with carbon ions than X‐rays. Our results may not be in conflict with a partial diminution of the role for NHEJ in high‐LET irradiated cells.14, 25 Our results also indicate that p53‐deficient cells, which may be resistant to carbon ions, might become a good candidate for the combination regimen of NU7441 and heavy ions. Inhibition of DNA‐PK, a key protein for NHEJ pathway, is known to impair DSB repair.9, 21 The nontoxic concentration (0.3 μM) of NU7441 did not seem to cause DNA repair inhibition in irradiated tumor cells, whereas 3 μM of NU7441, toxic to normal cells, clearly showed DSB repair inhibition (Fig. 2). We can suggest that a low and nontoxic concentration of DNA‐PK inhibitor might cause radio‐sensitization via a pathway other than inhibition of DSB repair. Our results somewhat reflect a previous study indicating that DNA‐PKcs knockdown cells induced radio‐sensitization, while there was no significant difference in DSB repair kinetics.24 These authors also reported that smaller amounts of DNA‐PKcs protein were accumulated at DSB sites in DNS‐PKcs knockdown cells and that this amount might be sufficient for DSB repair function. The detailed mechanism needs to be further examined, but DNA‐PK inhibition might have another role leading to an increase in cell death. One of the remarkable effects that the low concentration of NU7441 caused was the marked G2/M cell cycle arrest following irradiation. It is known that DNA‐PK inhibition increases the percentage of cells in the G2/M phase with low‐LET radiation.26 There is a possibility that DNA‐PK inhibition partially regulates the G2/M checkpoint pathway without affecting NHEJ. G2/M delay was more clearly manifested in p53‐null H1299 cells. G1 arrest is not normally observed in p53‐deficient cells27 and, thus, we think that with NU7441 treatment, more cells can be accumulated at G2/M in irradiated H1299 cells. In particular, this phenomenon was noted in carbon‐irradiated cells. These results suggest high‐LET heavy‐ion‐irradiated cells with a low concentration of NU7441 might be arrested in the G2/M phase regardless of NHEJ suppression. We also evaluated DNA fragmentation and cellular senescence. Irradiated H1299 cells with NU7441 showed a dramatic increase in the sub‐G1 population, especially 2 days after irradiation and beyond (Fig. 4). p53‐deficient H1299 cells induced a higher number of sub‐G1 cells than p53 wild‐type A549 cells in our case. Interestingly, these tendencies are similar to those of G2/M arrest and subsequent DNA fragmentation.28 We also believe that the marked G2/M arrest induced by DNA‐PK inhibition might cause DNA fragmentation. In addition, we found that NU7441 also promoted cellular senescence in irradiated H1299 cells (Fig. 5). Cellular senescence is a form of cellular growth control and this has been suggested as a strategy to deter tumor cell proliferation. The p53p21 pathway is the most essential senescence pathway,29 and we showed no p21 expression in H1299 cells. Several studies also indicated p53 independent senescence.30, 31 Thus, we also investigated p16 levels in H1299 cells as an important senescence pathway; however, the levels had no correlation with senescence induction (data not shown). Therefore, the enhanced senescence in H1299 cells via DNA‐PK inhibition might be caused by telomere dysfunction32, 33, 34 and mitosis skipping.35 In this senescence analysis, H1299 cells showed resistance to carbon ions compared to A549 cells (Fig. 5); however, NU7441 treatment caused more effective cell deaths in carbon‐irradiated H1299 cells. These results are consistent with cell survival, and indicate that p53 status would be an important factor when treatment options are considered. In summary, we found that a low concentration of DNA‐PK inhibitor NU7441, nontoxic to normal cells, caused a significant radio‐sensitization in irradiated tumor cells, independent of their p53 status. This is probably not from DSB repair inhibition but rather a consequence of strong G2/M arrest. A more detailed mechanism of this sensitization may be determined in the future. NU7441 caused effective radio‐sensitization in irradiated H1299 cells, which showed a slight radio‐resistant phenotype. These findings would provide a basis for future clinical application of a DNA‐PK inhibitor in radiation therapy including heavy ion treatment.

Disclosure Statement

The authors have no conflict of interest to declare.
  36 in total

1.  Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

Authors:  Philip M Reaper; Matthew R Griffiths; Joanna M Long; Jean-Damien Charrier; Somhairle Maccormick; Peter A Charlton; Julian M C Golec; John R Pollard
Journal:  Nat Chem Biol       Date:  2011-04-13       Impact factor: 15.040

2.  Wortmannin inhibits repair of DNA double-strand breaks in irradiated normal human cells.

Authors:  R Okayasu; K Suetomi; R L Ullrich
Journal:  Radiat Res       Date:  1998-05       Impact factor: 2.841

3.  Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.

Authors:  Michele Tavecchio; Joanne M Munck; Celine Cano; David R Newell; Nicola J Curtin
Journal:  Cancer Chemother Pharmacol       Date:  2011-06-01       Impact factor: 3.333

Review 4.  Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience.

Authors:  Tadashi Kamada; Hirohiko Tsujii; Eleanor A Blakely; Jürgen Debus; Wilfried De Neve; Marco Durante; Oliver Jäkel; Ramona Mayer; Roberto Orecchia; Richard Pötter; Stanislav Vatnitsky; William T Chu
Journal:  Lancet Oncol       Date:  2015-02       Impact factor: 41.316

5.  Cancer treatment: Sharp shooters.

Authors:  Vivien Marx
Journal:  Nature       Date:  2014-04-03       Impact factor: 49.962

6.  Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage.

Authors:  Christopher M Sturgeon; Zachary A Knight; Kevan M Shokat; Michel Roberge
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

7.  DNA-PKcs is critical for telomere capping.

Authors:  D Gilley; H Tanaka; M P Hande; A Kurimasa; G C Li; M Oshimura; D J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

8.  Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells.

Authors:  H Nagasawa; C Y Li; C G Maki; A C Imrich; J B Little
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

Review 9.  Senescence and aging: the critical roles of p53.

Authors:  A Rufini; P Tucci; I Celardo; G Melino
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

10.  Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo.

Authors:  Florence Debacq-Chainiaux; Jorge D Erusalimsky; Judith Campisi; Olivier Toussaint
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

View more
  12 in total

1.  Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence.

Authors:  Yue Liu; Elena V Efimova; Aishwarya Ramamurthy; Stephen J Kron
Journal:  J Cell Sci       Date:  2019-07-01       Impact factor: 5.285

Review 2.  Strategies to Enhance Radiosensitivity to Heavy Ion Radiation Therapy.

Authors:  Younghyun Lee; Ryuichi Okayasu
Journal:  Int J Part Ther       Date:  2018-09-21

3.  DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.

Authors:  Paulina Kopa; Anna Macieja; Elzbieta Pastwa; Ireneusz Majsterek; Tomasz Poplawski
Journal:  Mol Biol Rep       Date:  2021-01-02       Impact factor: 2.316

4.  Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.

Authors:  Tenley C Archer; Tobias Ehrenberger; Filip Mundt; Maxwell P Gold; Karsten Krug; Clarence K Mah; Elizabeth L Mahoney; Colin J Daniel; Alexander LeNail; Divya Ramamoorthy; Philipp Mertins; D R Mani; Hailei Zhang; Michael A Gillette; Karl Clauser; Michael Noble; Lauren C Tang; Jessica Pierre-François; Jacob Silterra; James Jensen; Pablo Tamayo; Andrey Korshunov; Stefan M Pfister; Marcel Kool; Paul A Northcott; Rosalie C Sears; Jonathan O Lipton; Steven A Carr; Jill P Mesirov; Scott L Pomeroy; Ernest Fraenkel
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

5.  Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation.

Authors:  Carmen Klein; Ivana Dokic; Andrea Mairani; Stewart Mein; Stephan Brons; Peter Häring; Thomas Haberer; Oliver Jäkel; Astrid Zimmermann; Frank Zenke; Andree Blaukat; Jürgen Debus; Amir Abdollahi
Journal:  Radiat Oncol       Date:  2017-12-29       Impact factor: 3.481

Review 6.  Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.

Authors:  Shigeaki Sunada; Akira Nakanishi; Yoshio Miki
Journal:  Cancer Sci       Date:  2018-03-06       Impact factor: 6.716

7.  Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.

Authors:  Jac A Nickoloff; Lynn Taylor; Neelam Sharma; Takamitsu A Kato
Journal:  Cancer Drug Resist       Date:  2021-06-19

8.  Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.

Authors:  Shigeaki Sunada; Hideki Kanai; Younghyun Lee; Takeshi Yasuda; Hirokazu Hirakawa; Cuihua Liu; Akira Fujimori; Mitsuru Uesaka; Ryuichi Okayasu
Journal:  Cancer Sci       Date:  2016-09-01       Impact factor: 6.716

Review 9.  Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.

Authors:  Mary Glorieux; Rüveyda Dok; Sandra Nuyts
Journal:  Oncotarget       Date:  2017-09-16

10.  Assessment of DNA-PKcs kinase activity by quantum dot-based microarray.

Authors:  Florian Lafont; Nizar Ayadi; Cathy Charlier; Pierre Weigel; Igor Nabiev; Houda Benhelli-Mokrani; Fabrice Fleury
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.